跳转至内容
Merck
CN

85256

Supelco

泰莫西芬

analytical standard

别名:

(Z)-1-(对二甲基氨基乙氧基苯基)-1,2-二苯基-1-丁烯, (Z)-2-[4-(1,2-二苯基-1-丁烯)苯氧基]-N,N-二甲基乙胺

登录查看公司和协议定价


About This Item

线性分子式:
C6H5C(C2H5)=C(C6H5)C6H4OCH2CH2N(CH3)2
CAS号:
分子量:
371.51
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

analytical standard

质量水平

方案

≥98.0% (HPLC)

保质期

limited shelf life, expiry date on the label

技术

HPLC: suitable
gas chromatography (GC): suitable

杂质

≤0.5% water

mp

97-98 °C (lit.)

应用

forensics and toxicology
pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

CC\C(c1ccccc1)=C(/c2ccccc2)c3ccc(OCCN(C)C)cc3

InChI

1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-

InChI key

NKANXQFJJICGDU-QPLCGJKRSA-N

基因信息

human ... ESR1(2099)

正在寻找类似产品? 访问 产品对比指南

应用

有关合适仪器技术的更多信息,请参考产品′分析证书。如需进一步支持,请联系技术服务。

生化/生理作用

乳腺中的雌激素拮抗剂。阻止乳腺肿瘤细胞中的雌二醇刺激的 VEGF 的产生。蛋白激酶 C 抑制剂。
蛋白激酶 C 抑制剂。诱发人类恶性神经胶质瘤细胞系的细胞凋亡。他莫昔芬及其代谢产物 4-羟基他莫昔芬是选择性雌激素反应调节剂 (SERM),在乳腺中用作雌激素拮抗剂。阻止乳腺肿瘤细胞中雌二醇刺激的 VEGF 的产生。

象形图

Health hazardEnvironment

警示用语:

Danger

危险声明

预防措施声明

危险分类

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Wataru Ise et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(32), 11792-11797 (2014-07-30)
In primary humoral responses, B-cell lymphoma 6 (Bcl6) is a master regulator of follicular helper T (TFH) cell differentiation; however, its activation mechanisms and role in memory responses remain unclear. Here we demonstrate that survival of CXCR5(+) TFH memory cells
Jack Cuzick et al.
The Lancet. Oncology, 16(1), 67-75 (2014-12-17)
Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in the first 10 years of follow-up. We report the long-term follow-up of the
Marcelo A Mori et al.
The Journal of clinical investigation, 124(8), 3339-3351 (2014-07-02)
miRNAs are important regulators of biological processes in many tissues, including the differentiation and function of brown and white adipocytes. The endoribonuclease dicer is a major component of the miRNA-processing pathway, and in adipose tissue, levels of dicer have been
P Saladores et al.
The pharmacogenomics journal, 15(1), 84-94 (2014-08-06)
Tamoxifen is the standard-of-care treatment for estrogen receptor-positive premenopausal breast cancer. We examined tamoxifen metabolism via blood metabolite concentrations and germline variations of CYP3A5, CYP2C9, CYP2C19 and CYP2D6 in 587 premenopausal patients (Asians, Middle Eastern Arabs, Caucasian-UK; median age 39
Karin Beelen et al.
Breast cancer research : BCR, 16(1), R13-R13 (2014-01-29)
Inhibitors of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway can overcome endocrine resistance in estrogen receptor (ER) α-positive breast cancer, but companion diagnostics indicating PI3K/AKT/mTOR activation and consequently endocrine resistance are lacking. PIK3CA mutations frequently occur in ERα-positive

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门